Informacja

Drogi użytkowniku, aplikacja do prawidłowego działania wymaga obsługi JavaScript. Proszę włącz obsługę JavaScript w Twojej przeglądarce.

Tytuł pozycji:

Hepatitis C Virus Infection: Host⁻Virus Interaction and Mechanisms of Viral Persistence.

Tytuł:
Hepatitis C Virus Infection: Host⁻Virus Interaction and Mechanisms of Viral Persistence.
Autorzy:
Chigbu DI; Department of Microbiology and Immunology, and the Institute for Molecular Medicine and Infectious Disease, Drexel University College of Medicine, 2900 West Queen Lane, Philadelphia, PA 19129, USA. .; Pennsylvania College of Optometry at Salus University, Elkins Park, PA 19027, USA. .
Loonawat R; Department of Microbiology and Immunology, and the Institute for Molecular Medicine and Infectious Disease, Drexel University College of Medicine, 2900 West Queen Lane, Philadelphia, PA 19129, USA. .
Sehgal M; Immunology, Microenvironment & Metastasis Program, The Wistar Institute, Philadelphia, PA 19104, USA. .
Patel D; Department of Microbiology and Immunology, and the Institute for Molecular Medicine and Infectious Disease, Drexel University College of Medicine, 2900 West Queen Lane, Philadelphia, PA 19129, USA. .
Jain P; Department of Microbiology and Immunology, and the Institute for Molecular Medicine and Infectious Disease, Drexel University College of Medicine, 2900 West Queen Lane, Philadelphia, PA 19129, USA. .
Źródło:
Cells [Cells] 2019 Apr 25; Vol. 8 (4). Date of Electronic Publication: 2019 Apr 25.
Typ publikacji:
Journal Article; Research Support, N.I.H., Extramural; Review
Język:
English
Imprint Name(s):
Original Publication: Basel, Switzerland : MDPI
MeSH Terms:
Hepacivirus/*metabolism
Hepatitis C/*immunology
Hepatitis C/*metabolism
Host Microbial Interactions/*physiology
Adaptive Immunity/immunology ; Antiviral Agents/metabolism ; Cytokines/metabolism ; Hepacivirus/genetics ; Hepacivirus/pathogenicity ; Hepatitis C/virology ; Hepatocytes/metabolism ; Humans ; Immunity, Innate/immunology ; Interferons/metabolism ; Killer Cells, Natural/immunology ; Liver Cirrhosis/immunology ; Toll-Like Receptors/metabolism
References:
J Exp Med. 2005 Jun 6;201(11):1725-31. (PMID: 15939788)
J Exp Med. 2003 Jun 16;197(12):1645-55. (PMID: 12810686)
J Gastroenterol Hepatol. 2008 Oct;23(10):1473-82. (PMID: 18761560)
Curr Pharm Des. 2008;14(17):1666-77. (PMID: 18673190)
Blood. 2001 May 15;97(10):3171-6. (PMID: 11342445)
HIV Med. 2011 Sep;12(8):487-93. (PMID: 21375685)
J Immunol. 2004 Nov 15;173(10):6072-81. (PMID: 15528343)
J Exp Med. 2005 Jun 6;201(11):1709-14. (PMID: 15939787)
Hepatology. 2002 Nov;36(5 Suppl 1):S237-44. (PMID: 12407599)
J Leukoc Biol. 2004 Oct;76(4):743-59. (PMID: 15218054)
Gastroenterology. 2015 Feb;148(2):392-402.e13. (PMID: 25447848)
Cell Discov. 2018 Sep 11;4:51. (PMID: 30210805)
Nature. 2006 Feb 9;439(7077):682-7. (PMID: 16382236)
Hepatology. 2003 Dec;38(6):1437-48. (PMID: 14647055)
J Immunol. 2002 Sep 15;169(6):3447-58. (PMID: 12218168)
J Virol. 2002 Sep;76(18):9345-54. (PMID: 12186917)
Clin Infect Dis. 2008 Apr 1;46(7):1046-52. (PMID: 18444822)
J Med Virol. 2005 Mar;75(3):402-11. (PMID: 15648076)
Microbiol Immunol. 2008 Oct;52(10):499-507. (PMID: 18822084)
Biol Chem. 2008 Oct;389(10):1283-98. (PMID: 18713016)
Nat Immunol. 2009 Jan;10(1):29-37. (PMID: 19043418)
Arch Biochem Biophys. 2007 Jun 15;462(2):254-65. (PMID: 17467654)
Dig Liver Dis. 2004 Nov;36(11):703-11. (PMID: 15570998)
Cell Mol Immunol. 2013 May;10(3):213-21. (PMID: 23524652)
Antiviral Res. 2017 Oct;146:139-145. (PMID: 28844749)
Science. 2004 Aug 6;305(5685):872-4. (PMID: 15297676)
Nat Immunol. 2013 Oct;14(10):986-95. (PMID: 24048120)
Gastroenterology. 2005 Apr;128(4):1034-41. (PMID: 15825084)
Proc Natl Acad Sci U S A. 2004 Nov 9;101(45):16004-9. (PMID: 15505208)
Hepatology. 2007 Aug;46(2):339-49. (PMID: 17559151)
Virology. 2003 Aug 1;312(2):320-9. (PMID: 12919737)
J Immunol. 2016 Mar 1;196(5):2283-92. (PMID: 26826241)
Eur J Immunol. 2004 Feb;34(2):438-46. (PMID: 14768048)
Annu Rev Immunol. 2013;31:563-604. (PMID: 23516985)
J Infect Dis. 2004 Dec 1;190(11):1919-26. (PMID: 15529255)
Gastroenterology. 2014 Oct;147(4):870-881.e8. (PMID: 25038432)
J Exp Med. 2006 Oct 30;203(11):2461-72. (PMID: 17030951)
Int J Tissue React. 1993;15(1):11-6. (PMID: 8282480)
Hepatoma Res. 2016;2:163-186. (PMID: 28042609)
J Immunol. 2004 Apr 15;172(8):4907-16. (PMID: 15067070)
J Leukoc Biol. 2007 Dec;82(6):1407-19. (PMID: 17881511)
Am J Pathol. 2005 Feb;166(2):443-53. (PMID: 15681828)
World J Gastroenterol. 2013 Nov 28;19(44):7889-95. (PMID: 24307783)
J Gastroenterol. 2011 Feb;46(2):232-41. (PMID: 20714907)
Eur J Immunol. 2000 Sep;30(9):2479-87. (PMID: 11009080)
J Med Virol. 2011 Jul;83(7):1159-64. (PMID: 21567419)
J Virol. 2002 Jul;76(14):6919-28. (PMID: 12072493)
Liver Int. 2016 Dec;36(12):1774-1782. (PMID: 27224844)
J Innate Immun. 2010;2(6):607-17. (PMID: 20714117)
Curr Top Microbiol Immunol. 2013;369:167-98. (PMID: 23463201)
J Virol. 2003 Jul;77(14):7843-55. (PMID: 12829824)
Med J Aust. 1992 Aug 17;157(4):231-3. (PMID: 1279365)
Immunology. 2007 Jun;121(2):283-92. (PMID: 17462079)
Hepatology. 2006 Oct;44(4):945-54. (PMID: 17006905)
Curr Drug Targets. 2017;18(7):826-843. (PMID: 26302811)
J Viral Hepat. 2013 Jun;20(6):385-94. (PMID: 23647955)
Expert Rev Anti Infect Ther. 2011 Sep;9(9):747-59. (PMID: 21905784)
Cell Death Dis. 2012 Nov 15;3:e419. (PMID: 23152055)
J Virol. 2013 Oct;87(19):10612-27. (PMID: 23885072)
Lancet Infect Dis. 2005 May;5(5):296-304. (PMID: 15854885)
Gastroenterology. 2007 Feb;132(2):654-66. (PMID: 17258733)
Immunol Rev. 2008 Jun;223:317-33. (PMID: 18613845)
Hepatology. 2004 Aug;40(2):335-45. (PMID: 15368438)
J Virol. 2006 Nov;80(22):11398-403. (PMID: 16956940)
Microbios. 2000;103(404):7-15. (PMID: 11034441)
J Virol. 2003 Aug;77(15):8299-309. (PMID: 12857899)
J Hepatol. 2002 Jul;37(1):101-8. (PMID: 12076868)
Science. 2001 May 4;292(5518):934-7. (PMID: 11340207)
Viruses. 2009 Sep;1(2):276-97. (PMID: 21994550)
J Exp Med. 1998 Dec 21;188(12):2205-13. (PMID: 9858507)
Nat Rev Immunol. 2009 Mar;9(3):162-74. (PMID: 19197294)
Eur J Immunol. 2007 Feb;37(2):445-55. (PMID: 17273991)
Proc Natl Acad Sci U S A. 2005 Feb 22;102(8):2992-7. (PMID: 15710891)
J Hepatol. 2008 Jun;48(6):903-13. (PMID: 18384906)
Nat Rev Immunol. 2015 Aug;15(8):471-85. (PMID: 26160613)
PLoS One. 2013;8(3):e59776. (PMID: 23527266)
Hepatology. 2007 Mar;45(3):588-601. (PMID: 17326153)
J Biol Chem. 2003 May 30;278(22):20358-66. (PMID: 12609975)
J Virol. 2001 Aug;75(15):7059-66. (PMID: 11435586)
Nature. 2015 Jan 1;517(7532):89-93. (PMID: 25307056)
Proc Natl Acad Sci U S A. 2005 Feb 22;102(8):2986-91. (PMID: 15710892)
Trends Immunol. 2006 Apr;27(4):195-201. (PMID: 16500147)
BMC Res Notes. 2014 Jan 08;7:12. (PMID: 24398031)
J Immunol. 2005 Dec 15;175(12):8226-35. (PMID: 16339562)
J Clin Microbiol. 2011 Jan;49(1):54-7. (PMID: 21084519)
Hepatology. 2006 Sep;44(3):736-45. (PMID: 16941702)
Intern Med. 2006;45(4):183-91. (PMID: 16543687)
J Virol. 2002 May;76(10):5062-70. (PMID: 11967322)
J Virol. 2006 May;80(9):4372-9. (PMID: 16611896)
Hepatology. 2008 Jul;48(1):48-58. (PMID: 18537195)
Nature. 2008 Jul 24;454(7203):523-7. (PMID: 18548002)
Hepatology. 2014 Oct;60(4):1170-9. (PMID: 24833036)
J Viral Hepat. 2007 Jul;14(7):492-502. (PMID: 17576391)
J Virol. 2011 Jan;85(1):596-605. (PMID: 20962076)
J Immunol. 2008 Dec 15;181(12):8215-25. (PMID: 19050238)
J Med Virol. 2002 Jun;67(2):152-61. (PMID: 11992576)
Immunol Rev. 2000 Apr;174:5-20. (PMID: 10807503)
J Virol. 2005 Oct;79(20):12979-88. (PMID: 16189000)
Eur J Immunol. 2005 Mar;35(3):738-45. (PMID: 15724249)
J Infect Dis. 2012 Mar 1;205(5):763-71. (PMID: 22293431)
Liver Transpl. 2006 Mar;12(3):363-72. (PMID: 16498647)
Intervirology. 2006;49(1-2):58-63. (PMID: 16166790)
J Virol. 2003 Feb;77(3):2251-7. (PMID: 12525661)
Gastroenterology. 2015 Jul;149(1):190-200.e2. (PMID: 25754160)
PLoS One. 2013 Apr 23;8(4):e62159. (PMID: 23626783)
Hepatology. 2008 Dec;48(6):1843-50. (PMID: 19003912)
Int J Med Sci. 2006;3(2):47-52. (PMID: 16614742)
Clin Exp Immunol. 1997 Sep;109(3):451-7. (PMID: 9328121)
Gut. 2006 Jun;55(6):869-77. (PMID: 16322112)
J Virol. 2006 Nov;80(22):11094-104. (PMID: 17071929)
Curr Hepat Rep. 2010;9(4):260-269. (PMID: 21258658)
Hepatology. 2002 Nov;36(5 Suppl 1):S3-20. (PMID: 12407572)
Hepatology. 2012 Feb;55(2):343-53. (PMID: 21953144)
Cancer Detect Prev. 1989;14(2):245-52. (PMID: 2559799)
Nat Rev Immunol. 2011 Oct 14;11(11):723-37. (PMID: 21997792)
Hepatology. 2004 Nov;40(5):1062-71. (PMID: 15486925)
J Clin Exp Hepatol. 2018 Jun;8(2):195-204. (PMID: 29892184)
Annu Rev Immunol. 2003;21:425-56. (PMID: 12615888)
Curr Top Microbiol Immunol. 2013;369:113-42. (PMID: 23463199)
Immunity. 2007 Oct;27(4):670-84. (PMID: 17950003)
J Exp Med. 2004 Aug 2;200(3):307-19. (PMID: 15289502)
J Hepatol. 1999 Jun;30(6):984-9. (PMID: 10406174)
Curr Opin Immunol. 2015 Aug;35:137-43. (PMID: 26241306)
Cancer Immunol Res. 2017 Jan;5(1):3-8. (PMID: 28052991)
Nat Med. 2006 Nov;12(11):1301-9. (PMID: 17041596)
Dig Dis. 2012;30 Suppl 1:48-54. (PMID: 23075868)
Science. 2003 Oct 24;302(5645):659-62. (PMID: 14576438)
Expert Opin Pharmacother. 2010 Apr;11(6):919-28. (PMID: 20166841)
J Clin Invest. 2004 Apr;113(7):963-72. (PMID: 15057302)
J Infect Dis. 2003 Jun 15;187(12):1951-8. (PMID: 12792872)
Hepatology. 2018 Dec;68(6):2078-2088. (PMID: 29704252)
Gut. 2003 Feb;52(2):307-14. (PMID: 12524419)
J Hepatol. 2006 Aug;45(2):190-6. (PMID: 16580086)
Gastroenterology. 2006 Nov;131(5):1584-91. (PMID: 17101330)
J Virol. 2003 Apr;77(8):4911-27. (PMID: 12663797)
J Hepatol. 2007 Sep;47(3):316-24. (PMID: 17475362)
Semin Liver Dis. 1995 Feb;15(1):41-63. (PMID: 7597443)
J Hepatol. 2014 Sep;61(3):538-43. (PMID: 24905492)
Annu Rev Immunol. 2001;19:683-765. (PMID: 11244051)
Front Immunol. 2018 Aug 02;9:1703. (PMID: 30116237)
Curr Top Microbiol Immunol. 2013;369:87-112. (PMID: 23463198)
PLoS Pathog. 2012;8(4):e1002653. (PMID: 22511875)
Cell. 2001 Aug 10;106(3):259-62. (PMID: 11509173)
Blood. 1996 Oct 1;88(7):2768-74. (PMID: 8839874)
Hepatol Res. 2008 Apr;38(4):354-61. (PMID: 18021223)
Clin Immunol. 2005 Oct;117(1):57-64. (PMID: 16006191)
Nature. 2009 Oct 8;461(7265):798-801. (PMID: 19759533)
FASEB J. 2003 Mar;17(3):488-90. (PMID: 12551851)
J Hepatol. 1998 Aug;29(2):207-13. (PMID: 9722201)
J Immunol. 2003 Feb 1;170(3):1249-56. (PMID: 12538683)
High Throughput. 2017 Oct 30;6(4):. (PMID: 29855459)
J Infect Dis. 2001 Jul 1;184(1):16-21. (PMID: 11398104)
Virology (Auckl). 2013 Feb 11;4:1-25. (PMID: 25512691)
PLoS Pathog. 2012;8(7):e1002832. (PMID: 22910833)
Proc Natl Acad Sci U S A. 2005 Dec 6;102(49):17717-22. (PMID: 16301520)
Gastroenterol Clin North Am. 2015 Dec;44(4):735-60. (PMID: 26600217)
Immunity. 2006 Sep;25(3):373-81. (PMID: 16979569)
J Exp Med. 2001 Nov 19;194(10):1395-406. (PMID: 11714747)
J Med Virol. 2007 Jun;79(6):724-33. (PMID: 17546694)
Expert Rev Vaccines. 2016 Dec;15(12):1535-1544. (PMID: 27267297)
J Virol. 2009 Jun;83(12):6149-60. (PMID: 19321602)
Clin Sci (Lond). 2008 Apr;114(7):457-66. (PMID: 18302533)
Immunol Rev. 2006 Jun;211:236-54. (PMID: 16824132)
Int J Radiat Oncol Biol Phys. 2008 Mar 15;70(4):1158-68. (PMID: 17881151)
Nat Rev Immunol. 2007 Jun;7(6):425-8. (PMID: 17525751)
Hepatology. 2005 Mar;41(3):643-51. (PMID: 15726647)
J Infect Dis. 2014 Feb 1;209(3):355-9. (PMID: 23964107)
Gastroenterol Clin North Am. 2015 Dec;44(4):717-34. (PMID: 26600216)
J Virol. 2006 Sep;80(18):9226-35. (PMID: 16940534)
J Virol. 2002 May;76(10):4792-7. (PMID: 11967296)
Nat Immunol. 2018 Feb;19(2):108-119. (PMID: 29348500)
Immunology. 2016 Aug;148(4):377-86. (PMID: 27149428)
J Exp Med. 2002 Jan 7;195(1):43-9. (PMID: 11781364)
Gastroenterology. 2010 Apr;138(4):1338-45, 1345.e1-7. (PMID: 20060832)
PLoS Pathog. 2013;9(4):e1003330. (PMID: 23633957)
Sci Transl Med. 2014 Nov 5;6(261):261ra153. (PMID: 25378645)
Proc Natl Acad Sci U S A. 2004 Sep 28;101(39):14067-72. (PMID: 15371595)
J Virol. 2008 Oct;82(20):9808-22. (PMID: 18667503)
J Virol. 2001 Jun;75(12):5550-8. (PMID: 11356962)
Proc Natl Acad Sci U S A. 2002 Nov 26;99(24):15661-8. (PMID: 12441397)
Hepatology. 2004 Jan;39(1):5-19. (PMID: 14752815)
Oncotarget. 2016 Jun 7;7(23):33796-808. (PMID: 27183919)
Proc Natl Acad Sci U S A. 1992 Apr 15;89(8):3468-72. (PMID: 1314389)
Immunity. 2014 Jul 17;41(1):49-61. (PMID: 25035953)
Immunology. 2010 Mar;129(3):363-74. (PMID: 19922426)
J Exp Med. 2000 May 1;191(9):1499-512. (PMID: 10790425)
Curr Top Microbiol Immunol. 2013;369:199-218. (PMID: 23463202)
Hepatology. 2004 Jul;40(1):108-14. (PMID: 15239092)
Lancet. 1999 Dec 18-25;354(9196):2119-24. (PMID: 10609818)
J Virol. 1994 Aug;68(8):4776-84. (PMID: 7518526)
Nat Med. 2000 May;6(5):578-82. (PMID: 10802716)
Nat Med. 2013 Jul;19(7):837-49. (PMID: 23836234)
Hepatology. 2016 May;63(5):1442-54. (PMID: 26513111)
Nat Rev Dis Primers. 2017 Mar 02;3:17006. (PMID: 28252637)
Gastroenterology. 1999 Oct;117(4):933-41. (PMID: 10500077)
J Clin Invest. 2000 Nov;106(10):1239-49. (PMID: 11086025)
Proc Natl Acad Sci U S A. 2004 Jul 6;101(27):10149-54. (PMID: 15220475)
J Hepatol. 1998 Jan;28(1):1-7. (PMID: 9537846)
Virology. 2007 Apr 25;361(1):161-73. (PMID: 17175001)
Nat Immunol. 2010 Oct;11(10):889-96. (PMID: 20856220)
Hepatology. 2009 Jan;49(1):12-21. (PMID: 19085909)
Annu Rev Immunol. 2001;19:65-91. (PMID: 11244031)
J Hepatol. 2008 Jan;48(1):51-60. (PMID: 17998148)
Am J Physiol Gastrointest Liver Physiol. 2009 Jun;296(6):G1324-31. (PMID: 19342509)
Hepatology. 2014 Jun;59(6):2140-51. (PMID: 24425349)
Curr HIV/AIDS Rep. 2015 Sep;12(3):353-61. (PMID: 26208812)
Infect Control Hosp Epidemiol. 2000 Apr;21(4):264-9. (PMID: 10782589)
Science. 1998 Oct 2;282(5386):103-7. (PMID: 9756471)
PLoS Pathog. 2010 Jun 10;6(6):e1000947. (PMID: 20548953)
J Virol. 2003 Feb;77(3):2134-46. (PMID: 12525648)
Cancer Lett. 2011 Jun 28;305(2):123-43. (PMID: 21168955)
PLoS One. 2017 Oct 17;12(10):e0186213. (PMID: 29040318)
J Immunol. 1997 Jun 1;158(11):5283-91. (PMID: 9164947)
Annu Rev Immunol. 2012;30:1-22. (PMID: 22136168)
J Virol. 1994 Mar;68(3):2026-30. (PMID: 8107266)
Hepatology. 2008 Jan;47(1):17-24. (PMID: 17941058)
J Med Virol. 2009 Apr;81(4):619-27. (PMID: 19235854)
J Clin Invest. 2004 Jul;114(2):250-9. (PMID: 15254592)
J Virol. 2016 Jan 06;90(6):3112-22. (PMID: 26739044)
Mol Cells. 2014 Jan;37(1):66-73. (PMID: 24552712)
Nature. 2005 Oct 20;437(7062):1167-72. (PMID: 16177806)
Clin Exp Immunol. 2004 Sep;137(3):559-65. (PMID: 15320906)
J Infect Dis. 2009 Mar 1;199(5):726-36. (PMID: 19199548)
Gastroenterology. 1997 Nov;113(5):1675-81. (PMID: 9352872)
J Virol. 2007 Mar;81(6):2545-53. (PMID: 17182670)
Front Immunol. 2018 Jun 28;9:1480. (PMID: 30002657)
Nature. 2005 Aug 18;436(7053):933-8. (PMID: 16107832)
Hepatology. 2016 Dec;64(6):1900-1910. (PMID: 27641977)
Grant Information:
R01 CA054559 United States CA NCI NIH HHS; R01 NS097147 United States NS NINDS NIH HHS
Contributed Indexing:
Keywords: HCV; NK cells; T cells; dendritic cells; immune dysregulation; interferons; viral persistence
Substance Nomenclature:
0 (Antiviral Agents)
0 (Cytokines)
0 (Toll-Like Receptors)
9008-11-1 (Interferons)
Entry Date(s):
Date Created: 20190428 Date Completed: 20200130 Latest Revision: 20200309
Update Code:
20240105
PubMed Central ID:
PMC6523734
DOI:
10.3390/cells8040376
PMID:
31027278
Czasopismo naukowe
Hepatitis C (HCV) is a major cause of liver disease, in which a third of individuals with chronic HCV infections may develop liver cirrhosis. In a chronic HCV infection, host immune factors along with the actions of HCV proteins that promote viral persistence and dysregulation of the immune system have an impact on immunopathogenesis of HCV-induced hepatitis. The genome of HCV encodes a single polyprotein, which is translated and processed into structural and nonstructural proteins. These HCV proteins are the target of the innate and adaptive immune system of the host. Retinoic acid-inducible gene-I (RIG-I)-like receptors and Toll-like receptors are the main pattern recognition receptors that recognize HCV pathogen-associated molecular patterns. This interaction results in a downstream cascade that generates antiviral cytokines including interferons. The cytolysis of HCV-infected hepatocytes is mediated by perforin and granzyme B secreted by cytotoxic T lymphocyte (CTL) and natural killer (NK) cells, whereas noncytolytic HCV clearance is mediated by interferon gamma (IFN-γ) secreted by CTL and NK cells. A host-HCV interaction determines whether the acute phase of an HCV infection will undergo complete resolution or progress to the development of viral persistence with a consequential progression to chronic HCV infection. Furthermore, these host-HCV interactions could pose a challenge to developing an HCV vaccine. This review will focus on the role of the innate and adaptive immunity in HCV infection, the failure of the immune response to clear an HCV infection, and the factors that promote viral persistence.
Zaloguj się, aby uzyskać dostęp do pełnego tekstu.

Ta witryna wykorzystuje pliki cookies do przechowywania informacji na Twoim komputerze. Pliki cookies stosujemy w celu świadczenia usług na najwyższym poziomie, w tym w sposób dostosowany do indywidualnych potrzeb. Korzystanie z witryny bez zmiany ustawień dotyczących cookies oznacza, że będą one zamieszczane w Twoim komputerze. W każdym momencie możesz dokonać zmiany ustawień dotyczących cookies